Purine analog toxicity in patients with hairy cell leukemia

References

• Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
   PubMed Web of Science ®Google Scholar
• Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F, et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116:595–597.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Ichim T, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf 2010;9:55–64.
   PubMed Web of Science ®Google Scholar
• Arons E, Sorbara L, Raffeld M, et al. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunol Immunother 2006;55:1100–1110.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol 2009;145:665–667.
   PubMed Web of Science ®Google Scholar
• Ruco L, Procopio A, Maccallini V, et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983;61:1132–1137.
   PubMed Web of Science ®Google Scholar
• Urba W, Baseler M, Kopp W, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989;73:38–46.
   PubMed Web of Science ®Google Scholar
• Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8:848–855.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997;11:42–47.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kurzrock R, Freireich E, Estey E. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906–2911.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83:3672–3681.
   PubMed Web of Science ®Google Scholar
• Schirmer M, Hilbe W, Geisen F, Thaler J, Konwalinka G. T cells and natural killer cells after treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine. Acta Haematol 1997;97:180–183.
   PubMed Web of Science ®Google Scholar
• Federico M, Zinzano PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002;20:638–646.
   PubMed Web of Science ®Google Scholar
• Hisada M, Chen B, Jaffe E, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007;99:215–222.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981–2986.
   PubMed Web of Science ®Google Scholar
• Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92:1160–1164.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–3015.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
   PubMed Web of Science ®Google Scholar
• Leupin N, Schuller JC, Solenthaler M, et al. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leuk Lymphoma 2010;51:613–619.
   PubMed Web of Science ®Google Scholar
• Todd SA, Morris TC, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma 2002;43:1343–1344.
   PubMed Web of Science ®Google Scholar
• Hassan R, Gupta M, Kern W, Ozer H. Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature. Leuk Lymphoma 2004;45:2149–2152.
   PubMed Web of Science ®Google Scholar
• Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010;24:2056–2062.
   PubMed Web of Science ®Google Scholar
• Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. Eur J Haematol 2001;66:7–10.
   PubMed Web of Science ®Google Scholar
• Siegel RS, Hakimian D, Spies W, et al. Technetium-99M sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosine. LeukLymphoma 1999;35:171–177.
   PubMed Web of Science ®Google Scholar
• Orlowsky RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 2004;45:187–188.
   PubMed Web of Science ®Google Scholar